Background: This study compares efficacy, safety and tolerability of 2 and 5 mg tropisetron in prevention of nausea and vomiting induced by low-dose cisplatin-or non-cisplatincontaining chemotherapy.
Introduction
Nausea and vomiting are among the most common and distressing side effects of cancer chemotherapy [1, 2] . The introduction of the 5-hydroxytryptamine (5-HT 3 ) receptor antagonists as antiemetic treatment gave an improvement in prevention of chemotherapy-induced nausea and vomiting but coincides with side effects, such as headache and constipation [3] . Tropisetron, one of the 5-HT 3 antagonists, is recommended at a 5-mg daily dose, to be given intravenously (i.v.) prior to the chemotherapy on day 1 and orally thereafter. This dose is based on dose finding studies with high-dose cisplatin-based chemotherapy [4] [5] [6] . However, no formal dose finding study with tropisetron has been performed for low-dose (<40 mg/m 2 ) cisplatin-or non-cisplatincontaining emetogenic chemotherapy regimens. The present study has been performed to investigate whether the low dose 2 mg of tropisetron is equally effective as the standard used daily dose of 5 mg for the prevention of emesis of low-dose cisplatin-or non-cisplatin-containing emetogenic chemotherapy.
Patients and methods

Study design
The study was designed as a prospective, multicentre, controlled, double-blind, randomized, parallel group trial.
Patient eligibility
Chemotherapy-naive patients between 18 and 75 years old were eligible if they were to receive at least one cycle of an emetogenic chemotherapy regimen for confirmed malignant disease, other than head and neck cancer. This chemotherapy had to be based on either monotherapy or combination regimens containing high-dose cyclophosphamide (>400 mg/m 2 i.v.), ifosfamide (>2.5 g/m 2 i.v.), doxo-rubicin (>50 mg/m 2 i.v.) or carboplatin (>400 mg/m 2 i.v. as monotherapy or > 300 mg/m 2 i.v. in combination regimens), administered during one to a maximum of five days or cisplatin <40 mg/m 2 i.v. per day, given for a maximum of five consecutive days. Local radiotherapy was only allowed if given prior to the chemotherapy. Patients with severe hepatic, renal or cardiac insufficiency were excluded, as were patients with uncontrolled infection, insufficiently controlled hypertension, drug or alcohol abuse, hypersensitivity reaction or drug allergy as well as clinical evidence of malignancy involving the central nervous system. Patients were also ineligible if they suffered from nausea or vomiting unrelated to chemotherapy. Concomitant treatment with drugs, which might affect emesis, was not permitted. The protocol was approved by the local ethics committee at each centre, and all patients gave informed consent.
Anti-emetic treatment
Patients were randomized per centre in a double-blind fashion to receive tropisetron (Navoban, Sandoz Pharma Ltd., Basle, Switzerland) either 2 mg or 5 mg i.v. on day 1 and one capsule of tropisetron orally once daily on days 2 to 6 of their first chemotherapy cycle. The 2-and 5-mg infusions and capsules had an identical appearance. Prior to the first chemotherapy, patients received tropisetron 2 or 5 mg diluted in 100 ml 0.9% NaCl as a 10-15 minutes i.v. infusion. On days 2 and 3 patients took one capsule tropisetron 2 or 5 mg orally, precisely 24 and 48 hours after the initial tropisetron dose on day 1. In addition, if chemotherapy was administered on day 2 or 3, in general this was given with the same interval and tropisetron was administered again prior to chemotherapy. On days 4, 5 and 6 patients took one capsule of tropisetron 2 or 5 mg in the morning.
Before treatment and at study end, laboratory evaluation was performed, and included hemoglobin, leucocyte and platelet counts, creatinine and liver enzyme tests. Values out of the clinically relevant ranges were classified as abnormal. For hematological parameters hemoglobin < 100 g/1, leucocytes <2.8 x 10 9 /l or platelets <75 x 10 9 /l were considered abnormal. Adverse events and comments made by the patients were also summarized.
Statistical methods
The Mantel-Haenszel test was used to test for differences in response between dosage groups when the data were categorical [7] .
Ordinal or continuous variables were tested with the van Elteren test for differences in response between dosage groups [8] . In the case of binary response, 95% confidence intervals were presented for proportions of responsive patients. The confidence intervals were based on a normal approximation to the binomial distribution [9] . Differences in adverse events were tested with the Chi-squaretest with a continuity correction according to Yates. No interim analysis was performed in this study. The calculation of the sample size was based on the assumption that the proportion of patients with total control of acute vomiting is 65% for the group receiving 5 mg tropisetron and for the group receiving 2 mg this would be at best 40%. A sample size of 69 patients per dosage group would provide 80% power to detect at the 0.05 significance level the difference of 40% versus 65% (2 mg versus 5 mg) in the proportion of patients to achieving total control of acute vomiting. Therefore, a total of 140 evaluable subjects, 70 in each arm were to be recruited, but in order to compensate for protocol violations, 152 patients were included.
Efficacy assessments
Only the first cycle of chemotherapy was studied. Primary efficacy parameters were control of acute (day 1) vomiting and nausea and control of delayed (days 2-6) vomiting and nausea for each of dose groups. Secondary efficacy parameters included overall control (days 1-6) of vomiting and nausea and control of vomiting and nausea summarized by chemotherapy regimen. However, with regard to overall control, multiple day regimens complicate the issues as one addresses delayed as well as anticipatory emesis on days 2-5, on top of acute emesis each day. Nausea was registered as duration in hours, rounded to the next 15 minutes. Vomiting was defined as either vomiting or retching and was counted in events. In a period of 15 minutes, a maximum of one vomiting event could be registered. Thus, the maximum number of vomiting events in 1 hour was four. The efficacy of antiemetic treatment on vomiting on a particular day was defined as total control (no events of vomiting), major control (one or two events), minor control (three or four events) and no control (five or more events). Also four categories of treatment response towards nausea on a particular day were defined; total control (< 15 minutes), major control (> 15 minutes to 4 hours), minor control (>4 hours to <8 hours) and no control (>8 hours). Days 1, 2 and 3 were defined as the 24-, 48-and 72-hour period following the start of chemotherapy treatment Days 4, 5 and 6 were defined as the consecutive 24-hour period starting at 7 a.m. Nausea, vomiting and adverse events were registered daily by the patient in a diary, and also comments could be stated daily. The study end was between days 6-10.
Safety assessments
Safety assessments consisted of a physical examination, vital signs and laboratory evaluations prior to treatment and at study end, as were adverse events and comments stated by the patients in the patient diaries. Vital signs parameters measured were weight, blood pressure and radial pulse. A systolic blood pressure > 170 mm Hg, a diastolic blood pressure > 100 mm Hg or a radial pulse > 120 beats per minute were classified as abnormal.
Results
Between May 1993 and September 1994,152 patients were randomized. Eight were withdrawn because of ineligibility before the start of the study, and consequently could not be included in the final analysis. Reasons elucidated for ineligibility before treatment were postponement of chemotherapy (n = 1), withdrawal of informed consent (n -1), pharmacist mistake (n = 1), ineligibility was found out after the study medication had been prepared already (n -3), not using study medication (n -1) and erroneous coadministration of standard antiemetic treatment (n = 1). The remaining 144 patients constituted the intention-to-treat (ill) population. In addition, 20 patients had a major protocol violation such as an insufficient chemotherapy regimen (n -7), previous chemotherapy (n -1) or co-administration of high-dose glucocorticoids (n -12). Therefore, the efficacy analysis population consisted of 124 patients. Primary efficacy analyses were carried out on all 144 patients in the 111 population as well as on all 124 patients in the efficacy analysis population. Safety evaluations were performed for all patients who received study medication.
Patient characteristics
The baseline characteristics of the two groups are shown in Table 1 . There were no significant differences between the groups. More women than men entered into the study since many of the chemotherapy regi-mens were specially targeted to treat breast cancer and gynecological tumors. The male patients mostly received chemotherapy for lung cancer. The main coexistent conditions were hypertension (n -19), insomnia (n = 7), anxiety, depression and nervousness (n -5), chronic obstructive pulmonary disease (n -6) and constipation (n -6). Most patients who received concomitant medication for coexistent diseases at entry continued their medication unaltered during the study. However, new medication was started sometimes, mainly for reasons of supportive care, such as pain relief or sleeping disorders. In addition, in 30 patients various antiemetic rescue treatments were given (18 in the 2-mg group and 14 in the 5-mg group; NS).
The chemotherapy regimens are listed in Table 2 . The chemotherapy regimens were converted into total daily doses and regimens were classified as cis-or carboplatin-based, cyclophosphamide-based or anthracycline-based. A regimen was defined as cyclophosphamide-based if the dose cyclophosphamide exceed- ed a total amount of 1000 mg, or if the total cyclophosphamide dose was <1000 mg and no anthracyclines were used, or the cyclophosphamide dose was equal to 1000 mg but the dose of epirubicin was <90 mg or the dose of doxorubicin was <75 mg. Any regimen containing ifosfamide was categorized as 'other'. All regimens not already classified and containing doxorubicin/epirubicin were then classified as anthracyclinebased. All patients received chemotherapy on day 1 and between 12% and 34% of the patients also received chemotherapy on each of days 2-5.
Efficacy evaluation Figure 1 shows the proportion of patients with total and major control of vomiting of each of days 1 to 6 per treatment arm. In the ITT population total control of acute vomiting (day 1) was achieved in 55% of the 2-mg group and 73% in the 5-mg group (P = 0.02). In the 2-mg group 12% of patients had minor control of acute vomiting and 19% had a treatment failure. In contrast, only 1% of the patients in the 5-mg group had minor control and 13% a treatment failure. Also for total plus major control there was a better control at 5 mg than at 2 mg (P = 0.02). The results of the efficacy analysis population were quite similar to those of the 111 population, the differences between the treatment groups were significant (P = 0.03 for total and P = 0.02 for total plus major control of acute vomiting). Figure 2 shows the percentage of patients with total and major control of nausea of each of days 1 to 6. Total control of acute nausea was obtained in 51% in the 2-mg group and in 70% in the 5-mg group (P = 0.03). Total or major control of acute nausea was achieved in 77% in the 2-mg group and in 91% in the 5-mg group (P = 0.004). The results of the efficacy analysis population were quite similar to those of the ITT population, the differences between the 2-and 5-mg groups were significant (P -0.03 for total control and P -0.003 for total or major control of acute nausea).
The total control of delayed vomiting (days 2 to 6 combined) in the 111 population was not significant different at 2 mg (51%) and 5 mg (69%) group. For the efficacy analysis population these figures were 51% and 64%, respectively (NS).
The total control of delayed nausea (days 2 to 6 combined) in the 111 population and the efficacy analysis population did also not significantly differ between both groups. (ITT population 42% at 2 mg and 56% at 5 mg, in the efficacy analysis population these amounts were 35% and 49%, respectively).
The overall outcome of vomiting (days 1-6 combined) in the 111 population was 35% total control in the 2-mg group and 59% in the 5-mg group (P = 0.007). Also for the efficacy analysis population total control of vomiting during all 6 days was worse in the 2-mg group (33%) than in the 5-mg group (54%; P -0.03). The overall outcome of total control of nausea (days 1-6 combined) in the 111 population did not differ between the groups (35% at 2 mg, 51% at 5 mg; NS). Also for the efficacy analysis patients the control of nausea during all 6 days of the chemotherapy course was not significantly different between the treatment arms.
Control of vomiting
In all chemotherapy regimens, except the cisplatinbased, the 5-mg group was superior in control of acute vomiting. In all chemotherapy regimens except the carboplatin-based, the efficacy of the 5-mg dose exceeded the 2-mg dose in control of acute nausea. Furthermore the efficacy rates ranged rather widely between the chemotherapy regimens, independent of the tropisetron dose given.
Safety evaluation
An overview of the adverse events is presented in Table  3 . Of the 210 adverse events, 155 were recorded by 92 patients in the patient diaries. No patient discontinued the tropisetron treatment because of an adverse event. Eight percent of the adverse events were attributed by the investigator to the antiemetic treatment, the remaining adverse events were assigned to the cancer or the sequelae of the chemotherapy. The most frequently reported adverse event by the patients was headache, mentioned by 37 (26%) patients; 12 (16%) of the 2-mg group and 25 (36%) of the 5-mg group (P < 0.05). Furthermore, a total of 21 (15%) patients recorded constipation, eight (11%) patients of the 2-mg group and 13 (19%) patients of the 5-mg group (NS). However, six patients had constipation entered as co-existent condition at entry, two in the 2-mg group and four in the 5-mg group. Two of these six patients had a recurrence during the study.
There were seven serious adverse events, according to the investigator not related to tropisetron, namely pneumothorax/catheter complication (n -1), agranulocytosis (n = 1), fatal pneumonia (n -1), lung embolism (n = 1), death due to rapid disease progression (n = 1), thrombosis of a subclavian vein (n -1) and paralytic ileus due to underlying cancer (n -1).
The physical examination revealed no adverse events due to treatment In addition, the observed changes in hematological parameters were attributed to the chemotherapy, and were not related to the antiemetic treatment.
Discussion
Management of chemotherapy-induced nausea and vomiting has improved since the availability of 5-HT 3 receptor antagonists, such as ondansetron, granisetron and tropisetron. Tropisetron is a 5-HT 3 antagonist and is also a weak antagonist for 5-HT 4 receptors [4] . It is administered once daily, which can be an advantage in a nauseated and vomiting patient. Tropisetron is administered orally, with a short i.v. infusion or with a slow i.v. injection, the recommended dose is 5 mg once daily [4, 5] . However, the lower limit of efficacy of tropisetron is unknown. The present dose-finding study shows that 5 mg tropisetron daily was more effective in the major control of acute nausea and vomiting than 2 mg. In the present study, no significant difference between both treatment arms towards delayed nausea and vomiting was observed. This is in accordance with previous studies, since the role of serotonin antagonists alone in control of delayed nausea and vomiting has its limitations [10] . When ondansetron was compared with high-dose metoclopramide in patients treated with cisplatin (50-100 mg/m 2 i.v.), no difference was obtained in the control of delayed vomiting, and metoclopramide was even superior in the control of delayed nausea. Patients preferred ondansetron, probably because of the lower frequency of side effects and the better control of acute nausea and vomiting [11, 12] . The combination of tropisetron with dexamethasone provides a better protection for delayed vomiting and nausea then tropisetron alone [13] [14] [15] . This has also been observed for ondansetron and granisetron [16] [17] [18] .
The efficacy rates of tropisetron varied considerably between the various chemotherapy regimens. It is not clear whether this is the result of the chemotherapy treatment alone or whether also the small patient numbers within some chemotherapy subgroups have contributed.
In the present study more side effects were observed in the 5-mg dose group, especially headache and constipation. These are known side effects of all 5-HT 3 antagonists [3] . In a comparative study of a single dose ondansetron, tropisetron or granisetron in the prevention of acute vomiting, no differences in prevalence of headache were obtained between the three study drugs [19] . Previously published data from a meta-analysis of tropisetron administered at 5 mg daily, showed that 27% of patients treated with this antiemetic drug reported headache, and 14% constipation [5] . In the current study the frequencies of these side effects in the 5-mg group are slightly higher, 36% for headache and 19% for constipation, whereas in the 2-mg group these figures are lower, 16% and 11%, respectively, suggesting a dose-response.
In conclusion, daily 5 mg tropisetron is more effec-tive than daily 2 mg in the prevention of acute vomiting and nausea induced by low-dose cisplatin or non-cisplatin containing chemotherapy. In addition, the 5-mg dose was more effective than the 2-mg regimen for overall control of vomiting. Notwithstanding the fact that tropisetron can be given safely, a daily dose of 5 mg tropisetron causes side effects, especially constipation and headache. In patients with these side effects co-medication with laxatives and/or analgetics should be considered. In patients with insufficient control of nausea and vomiting, tropisetron should be combined with another antiemetic drug.
